CompletedNCT00254202

Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia

Medication studyAges 18–65India + United States

The study in practice

Understand this study

Listed age limits: 18 years to 65 years.

Listed locations: Little Rock, United States · Anaheim, United States and 38 more locationsSee all locations and recruitment
Activities: Medication described in the protocol · Placebo comparator
Compensation: Payment and expense reimbursement have not been verified.

Study clarity

Study start dateStarted: November 18, 2005

Recruitment status: Completed
Enrollment listed in the registry: 593
Sponsor: Vanda Pharmaceuticals
Sponsor type: Unknown or unclear
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: United States, India
Age range: From 18 Years to 65 Years
Official registry ID: NCT00254202
Official title: Show the full official title
A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Iloperidone in Schizophrenic Patients in Acute Exacerbation Followed by a Long-term Treatment Phase.

Completed

Little Rock, United States · Anaheim, United States · Cerritos, United States

37 more locations

FAQ

Who is behind this study?

The study sponsor is Vanda Pharmaceuticals.

Did this study involve medication?

Yes. The study involved medication, including Iloperidone, Ziprasidone and Placebo.

Who was this study for?

Listed age limits: 18 years to 65 years.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.